Holen Sie sich die Stockscreener-App
3.97
12.78%
0.45
Vorhandelsmarkt:
3.95
-0.02
-0.50%
Schlusskurs vom Vortag:
$3.52
Offen:
$3.73
24-Stunden-Volumen:
7.65M
Relative Volume:
1.42
Marktkapitalisierung:
$596.97M
Einnahmen:
$4.21M
Nettoeinkommen (Verlust:
$-97.67M
KGV:
-4.2688
EPS:
-0.93
Netto-Cashflow:
$-70.76M
1W Leistung:
+20.67%
1M Leistung:
+19.58%
6M Leistung:
+31.02%
1J Leistung:
-1.24%
1-Tages-Spanne:
$3.63
$4.06
1-Wochen-Bereich:
$3.29
$4.06
52-Wochen-Spanne:
$2.01
$6.33
Absci Corp Stock (ABSI) Company Profile
Firmenname
Absci Corp
Sektor
Branche
Telefon
(360) 949-1041
Adresse
18105 SE MILL PLAIN BLVD, VANCOUVER
Vergleichen Sie ABSI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
3.97 | 529.31M | 4.21M | -97.67M | -70.76M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-02 | Eingeleitet | JP Morgan | Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-01-22 | Eingeleitet | Needham | Buy |
| 2024-10-02 | Eingeleitet | Guggenheim | Buy |
| 2024-07-03 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-07-18 | Eingeleitet | Truist | Buy |
| 2022-03-02 | Fortgesetzt | Cowen | Market Perform |
| 2022-02-01 | Eingeleitet | Berenberg | Buy |
| 2021-11-10 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-08-16 | Eingeleitet | BofA Securities | Neutral |
| 2021-08-16 | Eingeleitet | Cowen | Market Perform |
| 2021-08-16 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-16 | Eingeleitet | Stifel | Hold |
Alle ansehen
Absci Corp Aktie (ABSI) Neueste Nachrichten
Is Absci Poised for a Surge? - StocksToTrade
Absci, former U.S. soccer player Donovan announce partnership - TipRanks
Absci Corporation Partners with Landon Donovan to Address Androgenetic Alopecia and Advance Therapeutic Innovations - Quiver Quantitative
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research - GlobeNewswire
Absci (NASDAQ:ABSI) Transforms Biotechnology With AI Integration - Kalkine Media
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Is Absci (ABSI) Using ABS-201 To Quietly Prove The Value Of Its AI Drug Engine? - simplywall.st
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study - The Globe and Mail
Absci (NASDAQ:ABSI) Stock Price Up 10.8%Still a Buy? - MarketBeat
Absci doses first volunteers in phase 1/2a trial of hair loss antibody - Investing.com Nigeria
Absci doses first volunteers in phase 1/2a trial of hair loss antibody By Investing.com - Investing.com South Africa
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Assessing Absci (ABSI) Valuation After First Volunteers Dosed in ABS-201 HeadLINE Trial - simplywall.st
Absci Corp. Strives for New Horizons Amid Financial Adjustments - timothysykes.com
Absci announces first participants dosed in Phase 1/2a HEADLINE trial - TipRanks
Absci (ABSI): Assessing Valuation as AI‑Designed Hair Loss Drug Enters First Phase 1/2a Trial - Yahoo Finance
Absci Announces First Participants Dosed In Phase 1/2A Headline Trial - TradingView
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia - The Manila Times
Absci (Nasdaq: ABSI) doses first volunteers in Phase 1/2a ABS-201 hair loss trial - Stock Titan
Will Absci Corporation stock deliver shareholder valueJuly 2025 Opening Moves & AI Optimized Trade Strategies - Newser
Absci stock price target raised to $9 from $8 at Jones Trading By Investing.com - Investing.com South Africa
Absci stock price target raised to $9 from $8 at Jones Trading - Investing.com Canada
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $9 - 富途牛牛
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating - 富途牛牛
Absci Corp. Experiences Revision in Its Stock Evaluation Amid Mixed Financial Performance - Markets Mojo
Will Absci Corporation see short term momentumWeekly Trade Analysis & Risk Controlled Daily Trade Plans - newser.com
How Absci Corporation stock benefits from tech adoptionJuly 2025 Sector Moves & Low Risk High Win Rate Stock Picks - newser.com
Can trapped investors hope for a rebound in Absci CorporationGlobal Markets & Community Shared Stock Ideas - newser.com
Can Absci Corporation stock double in next 5 yearsMarket Growth Report & Expert Approved Momentum Trade Ideas - newser.com
Will Absci Corporation stock maintain growth storyJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - newser.com
Absci Corp’s Earnings Call Highlights Strategic Growth - MSN
Can Absci Corporation stock deliver sustainable ROE2025 Price Action Summary & Momentum Based Trading Ideas - newser.com
Absci (ABSI) Valuation in Focus as Clinical Expansion and Partnership Efforts Gather Pace - Yahoo Finance
Can Absci Corporation stock surprise with earnings upsideJuly 2025 Closing Moves & AI Powered Buy/Sell Recommendations - newser.com
Real time pattern detection on Absci Corporation stockPortfolio Update Summary & Proven Capital Preservation Methods - newser.com
Absci Corporation Advances AI-Driven Therapeutics - MSN
Absci’s Cash Reserves Bolster Future Financial Confidence - timothysykes.com
Absci Corporation (NASDAQ:ABSI) Q3 2025 Earnings Call Transcript - Insider Monkey
Absci Stock Takes a Leap: What’s Next? - StocksToTrade
Needham & Company LLC Cuts Absci (NASDAQ:ABSI) Price Target to $7.00 - MarketBeat
Why Absci Corporation stock remains a top recommendation2025 Key Lessons & Long-Term Growth Portfolio Plans - Fundação Cultural do Pará
Finanzdaten der Absci Corp-Aktie (ABSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):